Seeking Synergy of Checkpoint Blockade through TGFβ Inhibition

Immunotherapy, including checkpoint blockade, is revolutionizing the treatment of cancers, but efficacy has, however, been limited to a subset of patients and can be of limited duration due to primary and acquired resistance to treatment. An article in this issue shows that inhibiting TGF beta can overcome resistance to blockade of one immune checkpoint, but not another, unless one follows where the mechanism leads.